Novoste completes beta-Cath recruitment:
This article was originally published in Clinica
Executive Summary
Novoste has completed enrolment for its Phase I catheter irradiation trial for angioplasty at Emory University. The King Beta-Cath system is also under evaluation at Rhode Island Hospital, where two out of a total of eight patients have been treated. Novoste says there were no adverse events in the 15-patient Emory study. The system was designed by Dr Spencer King of Emory University in the hope that beta-radiation might prevent cell proliferation and vascular remodelling after angioplasty. Novoste raised $31 million in an initial public offering in May.